Details of the Drug

General Information of Drug (ID: DM5OHYE)

Drug Name
Bacitracin
Synonyms
Altracin; Baciguent; Baciquent; Citracin; Fortracin; Bacitracin A; Bacitracin A1; Bacitracin A2a; Neosporin (TN); Solu-Tracin 50; Partyl-, (10.4)-lactam; L-Asparagine, N-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucyl-D-.alpha.-glutamyl-L-isoleucyl-L-lysyl-D-ornithyl-L-isoleucyl-D-phenylalanyl-L-histidyl-D-.alpha.-as; 11702_FLUKA; 11702_SIGMA
Indication
Disease Entry ICD 11 Status REF
Blepharoconjunctivitis N.A. Approved [1]
Corneal abrasion NA06.4 Approved [1]
Keratitis N.A. Approved [1]
Skin infection 1F28-1G0Z Approved [2]
Therapeutic Class
Antibiotics
Affected Organisms
Enteric bacteria and other eubacteria
ATC Code
D06AX05: Bacitracin
D06AX: Other antibiotics for topical use
D06A: ANTIBIOTICS FOR TOPICAL USE
D06: ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D: DERMATOLOGICALS
J01XX10: Bacitracin
J01XX: Other antibacterials
J01X: OTHER ANTIBACTERIALS
J01: ANTIBACTERIALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
R02AB04: Bacitracin
R02AB: Antibiotics
R02A: THROAT PREPARATIONS
R02: THROAT PREPARATIONS
R: RESPIRATORY SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 5 Molecular Weight (mw) 1422.7
Logarithm of the Partition Coefficient (xlogp) -4.1
Rotatable Bond Count (rotbonds) 31
Hydrogen Bond Donor Count (hbonddonor) 17
Hydrogen Bond Acceptor Count (hbondacc) 21
Chemical Identifiers
Formula
C66H103N17O16S
IUPAC Name
(4R)-4-[[(2S)-2-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
Canonical SMILES
CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4
InChI
InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1
InChIKey
CLKOFPXJLQSYAH-ABRJDSQDSA-N
Cross-matching ID
PubChem CID
10909430
ChEBI ID
CHEBI:35862
CAS Number
1405-87-4
UNII
DDA3RRX0P7
DrugBank ID
DB00626
TTD ID
D0M1IO
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin-degrading enzyme (IDE) TT2EDHU IDE_HUMAN Inhibitor [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Endoglucanase A (EGA) DEK9LVM A0A660DUI5_9LACO Substrate [4]
Endoglucanase Y (EGY) DE2M583 A0A256VAC0_LACRE Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Bacitracin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Bacitracin caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [5]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Bacitracin and Inotersen. Amyloidosis [5D00] [6]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Bacitracin and Etidronic acid. Bone paget disease [FB85] [7]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Bacitracin and Iodipamide. Cholelithiasis [DC11] [8]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Bacitracin and Atracurium. Corneal disease [9A76-9A78] [9]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Bacitracin and Mivacurium. Corneal disease [9A76-9A78] [9]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Bacitracin and Pancuronium. Corneal disease [9A76-9A78] [9]
Tubocurarine DMBZIVP Moderate Additive neuromuscular blocking effects by the combination of Bacitracin and Tubocurarine. Corneal disease [9A76-9A78] [9]
Mycophenolic acid DMRBMAU Moderate Altered absorption of Bacitracin due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [10]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Bacitracin and Balsalazide. Indeterminate colitis [DD72] [11]
Ibandronate DM0QZBN Moderate Increased risk of nephrotoxicity by the combination of Bacitracin and Ibandronate. Low bone mass disorder [FB83] [12]
Clofarabine DMCVJ86 Moderate Increased risk of nephrotoxicity by the combination of Bacitracin and Clofarabine. Mature B-cell lymphoma [2A85] [13]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Bacitracin and Exjade. Mineral absorption/transport disorder [5C64] [14]
Pemetrexed DMMX2E6 Moderate Decreased renal excretion of Bacitracin caused by Pemetrexed mediated nephrotoxicity. Pleural mesothelioma [2C26] [15]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Bacitracin and Everolimus. Renal cell carcinoma [2C90] [16]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Bacitracin and Temsirolimus. Renal cell carcinoma [2C90] [16]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Bacitracin and Sulfasalazine. Rheumatoid arthritis [FA20] [11]
Pipecuronium DM5F84A Moderate Additive neuromuscular blocking effects by the combination of Bacitracin and Pipecuronium. Tonus and reflex abnormality [MB47] [9]
Doxacurium DMKE7L9 Moderate Additive neuromuscular blocking effects by the combination of Bacitracin and Doxacurium. Tonus and reflex abnormality [MB47] [9]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Bacitracin and Vecuronium. Tonus and reflex abnormality [MB47] [9]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Bacitracin and Rocuronium. Tonus and reflex abnormality [MB47] [9]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Bacitracin and Sirolimus. Transplant rejection [NE84] [16]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Bacitracin due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [10]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Bacitracin and Tacrolimus. Transplant rejection [NE84] [16]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Bacitracin and Olsalazine. Ulcerative colitis [DD71] [11]
⏷ Show the Full List of 25 DDI Information of This Drug

References

1 Bacitracin FDA Label
2 Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
3 Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci. 2004 Oct 27;24(43):9632-7.
4 Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
5 Cerner Multum, Inc. "Australian Product Information.".
6 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
7 Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
8 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
9 Huang KC, Heise A, Shrader AK, Tsueda K "Vancomycin enhances the neuromuscular blockade of vecuronium." Anesth Analg 71 (1990): 194-6. [PMID: 1973882]
10 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
11 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
12 Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D "Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity." Am J Kidney Dis 41 (2003): E18. [PMID: 12778436]
13 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
14 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
15 Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.
16 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.